Company Profile

Gemmus Pharma Inc
Profile last edited on: 4/8/2019      CAGE: 555B1      UEI: LWGXY5NQCNG6

Business Identifier: Treatment of influenza and other viral infectious diseases.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

409 Illinois Street Suite 4004
San Francisco, CA 94158
   (415) 978-2151
Location: Single
Congr. District: 11
County: San Francisco

Public Profile

Gemmus Pharma Inc., a biotechnology company, develops therapeutics for the treatment of influenza and other infectious diseases. The firm was founded to commercialize in-licensed technology from a major pharmaceutical company. Using a novel, host-directed approach, Gemmus target the underlying cause of debilitating symptoms associated with influenza and 'influenza-like-illness' (ILI) by modulating the natural immune response to the disease. Gemmus' lead candidate is a cardiovascular drug currently marketed in Asia that has been repurposed for use as a treatment for influenza. In 2014, Gemmus indicated plans to file an investigational new drug (IND) application with the FDA for treatment of influenza infections.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2010 1 NIH $231,231
Project Title: Gp1002 As A Highly Pathogenic Influenza A Therapeutic

Key People / Management

  Daryl H Faulds -- CEO

  William J Guilford -- President

  Agustin de la Calle -- VP, Business Development